Zhang Chunze, Li Xiaoting, Gao Dan, Ruan Haihua, Lin Zhenzhen, Li Xiaobo, Liu Guang, Ma Zhicheng, Li Xichuan
Department of Immunology, Tianjin Medical University, Tianjin, China.
Tianjin Union Medical Center, Tianjin, China.
Oncotarget. 2017 Jul 25;8(59):99394-99401. doi: 10.18632/oncotarget.19561. eCollection 2017 Nov 21.
It is reported recently Tropomyosin-related receptor Kinase B (TrkB) plays key roles in the anoikis resistance during the processes of tumorigenesis and metastasis. However, its prognostic significance for clinical patients remains inconclusive. In order to establish a correct and practicable link between increased TrkB and prognostication of human solid tumors, a meta-analysis was performed in this article. A systematic literature research in the electronic databases PubMed, Embase and Web of Science was performed to identify eligible studies. A fixed-effects meta-analytical model was employed to correlate TrkB expression with OS, DFS and clinicopathological features. A total of 11 studies covering 1516 patients with various solid tumors were recruited in this meta-analysis. TrkB over-expression was associated with poorer OS and poorer DFS in multivariate analysis. Additionally, the pooled odds ratios (ORs) indicated that TrkB over-expression was associated with large tumor size, lymph node metastasis, distant metastasis and a higher clinical stage. Overall, these results indicated that TrkB over-expression in patients with solid tumors might be related to poor prognosis and serve as a potential predictive marker of poor clinicopathological prognosis factor.
最近有报道称,原肌球蛋白相关受体激酶B(TrkB)在肿瘤发生和转移过程中的失巢凋亡抗性中起关键作用。然而,其对临床患者的预后意义仍不明确。为了在TrkB表达增加与人类实体瘤预后之间建立正确且可行的联系,本文进行了一项荟萃分析。我们在电子数据库PubMed、Embase和Web of Science中进行了系统的文献检索,以确定符合条件的研究。采用固定效应荟萃分析模型将TrkB表达与总生存期(OS)、无病生存期(DFS)及临床病理特征进行关联分析。本荟萃分析共纳入11项研究,涉及1516例患有各种实体瘤的患者。多因素分析显示,TrkB过表达与较差的OS和DFS相关。此外,合并的比值比(OR)表明,TrkB过表达与肿瘤体积大、淋巴结转移、远处转移及更高的临床分期相关。总体而言,这些结果表明,实体瘤患者中TrkB过表达可能与预后不良相关,并可作为临床病理预后不良因素的潜在预测标志物。